Portside Wealth Group’s Neurocrine Biosciences NBIX Stock Holding History

Portside Wealth Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Buy	+1,551	New	+$230K	0.03%	433

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Portside Wealth Group's NBIX Position: Q2 2026 in Review

Portside Wealth Group opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,551 shares worth $261K. The stake represents 0.03% of the portfolio and ranks #433 among its holdings.

84 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Portside Wealth Group held 1,551 shares of Neurocrine Biosciences worth $261K as of Q2 2026.
Neurocrine Biosciences was a new Portside Wealth Group position in Q2 2026.
Neurocrine Biosciences made up 0.03% of Portside Wealth Group's portfolio in Q2 2026, its #433 holding.
84 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Portside Wealth Group's 13F filing for Q2 2026, filed 14 Jul 2026.